Although further studies with longer follow-ups are necessary, positive immunostaining for CA19-9 in carcinoma lesions indicates that serum CA19-9 levels may serve as a surrogate tumor marker for PTC in place of the serum Tg levels in some patients if Tg cannot be used as a tumor marker as in patients who are TgAb-positive. Here, TG is linked to carcinoma.